ImmunoTek Commemorates International Plasma Awareness Week
ImmunoTek Bio Centers, the largest independent operator and developer of blood plasma donation centers in the United States, is thrilled to announce its participation in International Plasma Awareness Week (IPAW)…
2024 Antibody Drugs Market & Tech Report Leading Companies Profiled (Roche, J&J, AbbVie, Merck, Amgen)
The global antibody drug market was valued at $218.6 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 11.2%, reaching $412.1 billion by…
PBIRx Expands Leadership Team to Support Rapid Client and Account Growth
PBIRx, Inc., a leader in pharmacy benefit consulting and auditing, is proud to announce the promotion of Stacy Mathews, MBA, to Director of Account Management. Since joining PBIRx as a…
FDA Grants Approval to Fresenius Kabi and Formycon for Biosimilar Otulfi (ustekinumab-aauz)
Fresenius Kabi, a subsidiary of Fresenius specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, along with Formycon AG, a leading developer of…
Repare Therapeutics Presents Phase 1 Data on Camonsertib with Radiotherapy at ASTRO
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, recently announced promising data from a study evaluating camonsertib, an oral small molecule ATR inhibitor, in combination with palliative radiation…
SunLink Health Systems, Inc. Reports Fiscal 2024 Q4 and Annual Financial Results
SunLink Health Systems, Inc. (NYSE American: SSY) today reported a loss from continuing operations of $652,000 (or $0.09 per diluted share) for the fourth fiscal quarter ended June 30, 2024,…
Lupin Partners with Celnova to Distribute Orphan Drug NaMuscla
Lupin Limited, a leading global pharmaceutical company, has announced that its subsidiary, Lupin Atlantis Holdings SA, has entered into a distribution agreement with Celnova Pharma for the commercialization of its…
FDA Approves KarXT, a PureTech-Invented Treatment for Schizophrenia in Adults
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company committed to improving the lives of patients with serious diseases, announced today that KarXT (a combination of xanomeline and…
Odyssey Therapeutics Announces Formation of Scientific Advisory Board
Odyssey Therapeutics, Inc., a biotechnology firm at the forefront of developing next-generation precision immunomodulators for inflammatory conditions, has announced the establishment of its Scientific Advisory Board (SAB). This board features…
GE HealthCare Gets FDA Approval for Flyrcado PET Radiotracer to Improve Coronary Artery Disease Diagnosis
GE HealthCare (Nasdaq: GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, marking a significant advancement in positron emission tomography (PET) myocardial perfusion…
Artera to Present MMAI Platform Insights for Oligometastatic Prostate Cancer at ASTRO 2024
Artera, a pioneer in multimodal artificial intelligence (MMAI) for prognostic and predictive cancer testing, is set to present two oral abstracts at the 2024 American Society for Radiation Oncology (ASTRO)…
Dupixent (dupilumab) Becomes the First Biologic Treatment Approved in the U.S. for COPD Patients
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adults with inadequately…